Original Article

Trends in Premature Deaths among Women Living with HIV/AIDS and Cervical Cancer

Authors: Emmanuella Oduguwa, BS, Deepa Dongarwar, MS, Hamisu M. Salihu, MD, PhD


Objectives: There is a lack of updated information on premature death and years of potential life lost (YPLL) among human immunodeficiency (HIV)–positive women with cervical cancer. We hypothesize that increased access to preventive resources such as antiretroviral therapy, preexposure prophylaxis, and human papillomavirus vaccines has reduced premature mortality and YPLL in these women in the previous decades.

Methods: We used data from the National Inpatient Sample database from 2003 to the third quarter of 2015, and restricted the analysis to HIV-positive women with or without cervical cancer. Joinpoint regression models were run to identify trends in the rates of HIV and cervical cancer. Overall and age-stratified YPLL were calculated for HIV-positive women with cervical cancer. Adjusted survey logistic regression models were built to determine the predictive factors of in-hospital mortality among women living with HIV.

Results: Among hospitalized women, low-income, non-Hispanic Blacks, and patients aged 40 to 59 years experienced greater frequencies of HIV/cervical cancer comorbidity. The prevalence of HIV hospitalizations increased by an average annual percentage of 0.9% (95% confidence interval 0.3–1.6). YPLL decreased in HIV-positive women living with and without cervical cancer by 4.9% and 4.3%, respectively. The trajectory for YPLL was not uniform across age groups. YPLL decreased substantially in women aged 20 to 29 years with HIV/cervical cancer comorbidity. Cervical cancer remained a significant predictor of mortality among HIV-positive women when adjusted for age, race, and insurance coverage.

Conclusions: Within a large, national sample from 2003 to 2015, we found an overall declining trend in YPLL in women living with HIV/cervical cancer comorbidity. In-hospital mortality among HIV-positive women was associated with cervical cancer, age, race, and insurance coverage. We recommend further investigation into the quality of HIV and cervical cancer treatment and prevention services for the sociodemographic groups described.
Posted in: Infectious Disease90 Acquired Immunodeficiency Syndrome (AIDS) And Human Immunodeficiency Virus (HIV) Infection12 Gynecologic Cancer6

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.


1. Kim SC, Feldman S, Moscicki AB. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention. Rheumatology (Oxford) 2018;57(suppl 5):v26–v33. 2. Centers for Disease Control and Prevention. Human papillomavirus. About HPV. https://www.cdc.gov/hpv/parents/about-hpv.html?CDC_AA_refVal= https%3A%2F%2Fwww.cdc.gov%2Fhpv%2Fparents%2Fwhatishpv.html. Published April 29, 2019. Accessed February 13, 2020. 3. Mendes Lobão W, Duarte FG, Burns JD, et al. Low coverage of HPV vaccination in the national immunization programme in Brazil: parental vaccine refusal or barriers in health-service based vaccine delivery? PLoS One 2018;13:e0206726. 4. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Heal 2020;8:e191–e203. 5. Centers for Disease Control and Prevention. Genital HPV Infection – CDC Fact Sheet. https://www.cdc.gov/std/hpv/hpv-Fs-July-2017.pdf. Accessed October 9, 2020. 6. Song D, Li H, Li H, et al. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncol Lett 2015;10:600–606. 7. Centers for Disease Control and Prevention. What Are the Risk Factors for Cervical Cancer? https://www.cdc.gov/cancer/cervical/basic_info/risk_factors.htm. Published August 7, 2019. Accessed February 13, 2020. 8. Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS 2018;32:795–808. 9. Joint United Nations Programme on HIV/AIDS (UNAIDS). Go Further partnership reaches over half a million HIV-positive. https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/ september/20190925_go-further-partnership. Published September 25, 2019. Accessed February 13, 2020. 10. Gross JJ. Update on the epidemiology and prevention of HIV/AIDS in the United States. Curr Epidemiol Rep 2016;34:352–359. 11. Moore RD. Epidemiology of HIV infection in the United States: implications for linkage to care. Clin Infect Dis 2011;52(suppl 2):S208–S213. 12. Valdiserri RO, Forsyth AD, Yakovchenko V, et al. Measuring what matters: development of standard HIV core indicators across the U.S. Department of Health and Human Services. Public Health Rep 2013;128:354–359. 13. McGraw SL, Ferrante JM. Update on prevention and screening of cervical cancer. World J Clin Oncol 2014;5:744–752. 14. Gardner J, Sanborn J. Years of potential life lost (YPLL)—what does it measure? Epidemiology 1990;1:322–329. 15. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the US: a ten-year study. J Acquir Immune Defic Syndr 2010;51:399–406. 16. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS 2014;28:453–465. 17. Landy R, Pesola F, Castañón A, et al. Impact of cervical screening on cervical cancer mortality: estimation using stage-specific results from a nested case-control study. Br J Cancer 2016;115:1140–1146. 18. Coghill AE, Shiels MS, Suneja G, et al. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol 2015;33:2376–2383. 19. Lai D, Hardy RJ. Potential gains in life expectancy or years of potential life lost: impact of competing risks of death. Int J Epidemiol 1999;28:894–898. 20. Selik RM, Chu SY. Years of potential life lost due to HIV infection in the United States. AIDS 1997;11:1635–1639. 21. Centers for Disease Control and Prevention. Quarterly report to the Domestic Policy Council on the prevalence and rate of spread of HIV and AIDS–United States. MMWR Morb Mortal Wkly Rep 1988;37:551–554, 559. 22. Schwartz E, Kofie VY, Rivo M, et al. Black/white comparisons of deaths preventable by medical intervention: United States and the District of Columbia 1980-1986. Int J Epidemiol 1990;19:591–598. 23. Bhatti AB, Usman M, Kandi V. Current scenario of HIV/AIDS, treatment options, and major challenges with compliance to antiretroviral therapy. Cureus 2016;8:1–12. 24. Weinstein M, Yang OO, Cohen AC. Were we prepared for PrEP? Five years of implementation. AIDS 2017;31:2303–2305. 25. Ghebre RG, Grover S, Xu MJ, et al. Cervical cancer control in HIV-infected women: past, present and future. Gynecol Oncol Rep 2017;21:101–108. 26. Social Security Admistration. Actuarial life table. http://www.ssa.gov/oact/STATS/table4c6.html. Accessed October 9, 2020. 27. Healthcare Cost and Utilization Project. NIS Description of Data Elements. DXn - ICD-9-CM  Diagnosis. https://www.hcup-us.ahrq.gov/db/vars/dxn/nisnote.jsp. Accessed August 3, 2020. 28. Benard VB, Watson M, Castle PE, et al. Cervical carcinoma rates among young females in the United States. Obstet Gynecol 2012;120:1117–1123. 29. World Health Organization. HIVand Adolescents: Guidance for HIV Testing and Counselling and Care for Adolescents Living with HIV. Geneva: World Health Organization; 2013. 30. Mogtomo MLK, Malieugoue LCG, Djiepgang C, et al. Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. Infect Agent Cancer 2009;4:9. 31. Keller MJ, Burk RD, Xie X, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. JAMA 2012;308:362–369. 32. Ononogbu U, Almujtaba M, Modibbo F, et al. Cervical cancer risk factors among HIV-infected Nigerian women. BMC Public Health 2013;13:582. 33. Belglaiaa E, Souho T, Badaoui L, et al. Awareness of cervical cancer among women attending an HIV treatment centre: a cross-sectional study from Morocco. BMJ Open 2018;8:e020343. 34. Serraino D, Dal Maso L, La Vecchia C, et al. Invasive cervical cancer as an AIDS-defining illness in Europe. AIDS 2002;16:781–786. 35. Leece P, Kendall C, Touchie C, et al. Cervical cancer screening among HIV-positive women. Retrospective cohort study from a tertiary care HIV clinic. Can Fam Physician 2010;56:e425–e431. 36. Adjorlolo-Johnson G, Unger ER, Boni-Ouattara E, et al. Assessing the relationship between HIV infection and cervical cancer in Côte d’Ivoire: a case-control study. BMC Infect Dis 2010;10:242. 37. Nkambule BB, Davison G, Ipp H. Platelet leukocyte aggregates and markers of platelet aggregation, immune activation and disease progression in HIV infected treatment naive asymptomatic individuals. J Thromb Thrombolysis 2015;40:458–467. 38. Shakil O, Chakrabarty BK, Nagaraja N. Universal health coverage - there is more to it than meets the eye. J Fam Med Prim Care 2017;6:169–170. 39. Heslin KC, Elixhauser A. HIV hospital stays in the United States, 2006–2013. Statistical Brief #206. http://www.ncbi.nlm.nih.gov/pubmed/27559565. Accessed October 9, 2020. 40. Corma S, Nwankwo C, Kebede N, et al. Inpatient burden of cervical and uterine cancer in the United States. J Clin Oncol 2019;37(suppl e17009). 41. Ogunmola OJ, Oladosu YO, Olamoyegun MA. Relationship between socioeconomic status and HIV infection in a rural tertiary health center. HIV/AIDS (Auckl) 2014;6:61–67. 42. Centers for Disease Control and Prevention. Mortality among blacks or African Americans with HIV infection—United States, 2008–2012. MMWR Morb Mortal Wkly Rep 2015;64:81–86. 43. Gauri A, Messiah SE, Bouzoubaa LA, et al. Cervical cancer sociodemographic and diagnostic disparities in Florida: a population-based study (1981–2013) by stage at presentation. Ethn Health 2018;25:995–1003. 44. Shin JY, Yoon JK, Diaz AZ. Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients. J Neurooncol 2017;132:89–98. 45. Blondell SJ, Kitter B, Griffin MP, et al. Barriers and facilitators to HIV testing in migrants in high-income countries: a systematic review. AIDS Behav 2015;19:2012–2024. 46. Andersen I, Kolodziejczyk C, Thielen K, et al. The effect of breast cancer on personal income three years after diagnosis by cancer stage and education: a register-based cohort study among Danish females. BMC Public Health 2015;15:50. 47. Bahadori M, Raadabadi M, Salimi M, et al. Discharge against medical advice: a case study in a public teaching hospital in Tehran, Iran in 2012. Glob J Health Sci 2013;5:179–185. 48. Anis AH, Sun H, Guh DP, et al. Leaving hospital against medical advice among HIV-positive patients. CMAJ 2002;167:633–637. 49. Feder J, Levitt L, O'Brien E, et al. Covering the low-income uninsured: the case for expanding public programs. Health Aff 2001;20:27–39. 50. Yuan S, Ashmore S, Chaudhary KR, et al. The role of socioeconomic status in individuals that leave against medical advice. S D Med 2018;71:214–219. 51. Boyd AD, Li J, Kenost C, et al. ICD-10 procedure codes produce transition challenges. AMIA Jt Summits Transl Sci Proc 2018;2017:35–44. 52. Monestime JP, Mayer RW, Blackwood A. Analyzing the ICD-10-CM transition and post-implementation stages: a public health institution case study. Perspect Health Inf Manag 2019;16:1a